[go: up one dir, main page]

MX2016007170A - Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma). - Google Patents

Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma).

Info

Publication number
MX2016007170A
MX2016007170A MX2016007170A MX2016007170A MX2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A
Authority
MX
Mexico
Prior art keywords
aml
myeloid leukemia
acute myeloid
combination treatment
novel combination
Prior art date
Application number
MX2016007170A
Other languages
English (en)
Other versions
MX370618B (es
Inventor
Higgins Brian
Nichols Gwen
E Packman Kathryn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52014047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016007170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016007170A publication Critical patent/MX2016007170A/es
Publication of MX370618B publication Critical patent/MX370618B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se refiere a un producto farmacéutico que comprende: a) como primer componente un inhibidor de la interacción MDM2-p53, y b) como segundo componente, citarabina, como preparación combinada para la utilización secuencial o simultánea en el tratamiento del cáncer, particularmente de la LMA.
MX2016007170A 2013-12-05 2014-12-01 Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma). MX370618B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912152P 2013-12-05 2013-12-05
PCT/EP2014/076063 WO2015082384A1 (en) 2013-12-05 2014-12-01 Novel combination treatment for acute myeloid leukemia (aml)

Publications (2)

Publication Number Publication Date
MX2016007170A true MX2016007170A (es) 2016-09-08
MX370618B MX370618B (es) 2019-12-17

Family

ID=52014047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007170A MX370618B (es) 2013-12-05 2014-12-01 Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma).

Country Status (30)

Country Link
US (5) US20160303158A1 (es)
EP (1) EP3077004B1 (es)
JP (3) JP6297695B2 (es)
KR (1) KR101862955B1 (es)
CN (1) CN105792847B (es)
AR (1) AR098576A1 (es)
AU (1) AU2014359422B2 (es)
BR (1) BR112016009669B1 (es)
CA (1) CA2926307C (es)
CL (1) CL2016001345A1 (es)
CR (1) CR20160173A (es)
DK (1) DK3077004T3 (es)
EA (1) EA201690785A1 (es)
ES (1) ES2785203T3 (es)
HR (1) HRP20200566T1 (es)
HU (1) HUE049434T2 (es)
IL (1) IL244888B (es)
LT (1) LT3077004T (es)
MA (1) MA39040A1 (es)
MX (1) MX370618B (es)
PE (1) PE20160591A1 (es)
PH (1) PH12016500933A1 (es)
PL (1) PL3077004T3 (es)
PT (1) PT3077004T (es)
RS (1) RS60142B1 (es)
SG (1) SG11201604504VA (es)
SI (1) SI3077004T1 (es)
TW (2) TWI627954B (es)
WO (1) WO2015082384A1 (es)
ZA (1) ZA201602829B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
EP2768518A4 (en) 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
ES2785203T3 (es) * 2013-12-05 2020-10-06 Hoffmann La Roche Tratamiento de combinación novedoso para leucemia mielógena aguda (LMA)
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途
US20170114098A1 (en) * 2015-09-03 2017-04-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
JP7163281B2 (ja) * 2016-06-06 2022-10-31 セルジーン コーポレイション ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドによる血液系悪性腫瘍の治療
JP6848047B2 (ja) * 2016-08-08 2021-03-24 フェイ シアオ， スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用
RU2762573C2 (ru) 2016-11-15 2021-12-21 Новартис Аг Доза и режим введения для ингибиторов взаимодействия hdm2 с p53
WO2018178925A1 (en) * 2017-03-31 2018-10-04 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3858361B1 (en) 2018-09-28 2025-10-08 FUJIFILM Corporation Antitumor agent containing cytarabine, antitumor effect enhancer used in combination with cytarabine, antitumor kit, and antitumor agent used in combination with cytarabine
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN112294965B (zh) 2019-07-26 2023-03-14 苏州亚盛药业有限公司 Mdm2抑制剂的药物组合物及其在预防和/或治疗疾病中的用途
US20250073266A1 (en) * 2021-05-13 2025-03-06 Nkarta, Inc. Dosing regimens for cancer immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60318198T2 (de) * 2002-05-02 2008-12-04 Merck & Co., Inc. Tyrosinkinase-hemmer
DE102005012681A1 (de) * 2005-03-18 2006-09-21 Weber, Lutz, Dr. Neue 1,5-Dihydro-pyrrol-2-one
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN101773408B (zh) * 2010-01-15 2012-04-04 平荧 多功能排针结合电凝固技术提升下垂皮肤的装置
RU2012147597A (ru) * 2010-04-09 2014-05-20 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
ES2785203T3 (es) * 2013-12-05 2020-10-06 Hoffmann La Roche Tratamiento de combinación novedoso para leucemia mielógena aguda (LMA)
US9657351B2 (en) * 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist

Also Published As

Publication number Publication date
MA39040A1 (fr) 2018-01-31
KR20160070190A (ko) 2016-06-17
PT3077004T (pt) 2020-04-16
SG11201604504VA (en) 2016-07-28
PL3077004T3 (pl) 2020-08-10
TWI627954B (zh) 2018-07-01
EP3077004B1 (en) 2020-02-19
JP2016539160A (ja) 2016-12-15
US20160303158A1 (en) 2016-10-20
TWI678204B (zh) 2019-12-01
CA2926307A1 (en) 2015-06-11
JP2018111700A (ja) 2018-07-19
IL244888B (en) 2020-11-30
CN105792847B (zh) 2019-11-08
EP3077004A1 (en) 2016-10-12
US20230381215A1 (en) 2023-11-30
CA2926307C (en) 2021-11-16
AU2014359422B2 (en) 2020-03-05
KR101862955B1 (ko) 2018-05-31
US20150157603A1 (en) 2015-06-11
HK1222808A1 (zh) 2017-07-14
HRP20200566T1 (hr) 2020-06-26
BR112016009669B1 (pt) 2023-01-24
US9956243B2 (en) 2018-05-01
DK3077004T3 (da) 2020-04-27
EA201690785A1 (ru) 2016-10-31
ES2785203T3 (es) 2020-10-06
JP6297695B2 (ja) 2018-03-20
MX370618B (es) 2019-12-17
LT3077004T (lt) 2020-05-11
BR112016009669A8 (pt) 2020-04-07
PE20160591A1 (es) 2016-06-11
HUE049434T2 (hu) 2020-09-28
IL244888A0 (en) 2016-05-31
TW201840310A (zh) 2018-11-16
JP2021091690A (ja) 2021-06-17
PH12016500933A1 (en) 2016-06-27
WO2015082384A1 (en) 2015-06-11
ZA201602829B (en) 2017-04-26
JP6918724B2 (ja) 2021-08-11
TW201526890A (zh) 2015-07-16
RS60142B1 (sr) 2020-05-29
CR20160173A (es) 2016-06-08
US20200253999A1 (en) 2020-08-13
CN105792847A (zh) 2016-07-20
AR098576A1 (es) 2016-06-01
SI3077004T1 (sl) 2020-07-31
CL2016001345A1 (es) 2017-04-07
US20220031726A1 (en) 2022-02-03
AU2014359422A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
PH12016500933A1 (en) Novel combination treatment for acute myeloid leukemia (aml)
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
TW201614068A (en) Fucosidase from bacteroides and methods using the same
PH12016500137B1 (en) Afucosylated anti-fgfr2iiib antibodies
MX2020009919A (es) Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de pi3 cinasa.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX2019015527A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
WO2014177464A3 (en) Inhibitors of nhr2 and/or runx1/eto-tetramerization
MX2016001683A (es) Combinaciones de inhibidores de quinasa pim.
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
MX2015016603A (es) Composiciones de corticosteroides.
NZ717192A (en) Anti-inflammatory tripeptides
MX356102B (es) Compuestos y métodos para tratar leucemia.
WO2015027121A3 (en) Cancer treatment
PH12017501979A1 (en) Pharmaceutical compound
IN2014MU00495A (es)
MX2015013736A (es) Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemia por deficiencia de hierro.
NZ725303A (en) Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer
IN2013CH00453A (es)
UA116811C2 (uk) Комплекси агомелатину та сульфонових кислот, спосіб їх одержання та фармацевтичні композиції, що їх містять

Legal Events

Date Code Title Description
FG Grant or registration